For decades, the standard options for cancer treatment in India followed a familiar pattern — surgery, radiation, and chemotherapy. These remain important tools. But something significant has changed in the last two to three years that every patient, caregiver, and family navigating a cancer diagnosis should be aware of.
Advanced cancer therapies — including immunotherapy, targeted therapy, and cellular treatments like CAR T-cell therapy — are now accessible in India in ways they simply were not before. Understanding what these treatments are, what they are designed to do, and when they become relevant is increasingly important information for any family dealing with a cancer diagnosis.
Why the Treatment Landscape Has Shifted
CAR T-cell therapy is improving quickly. By 2026 it is safer, more effective, and reaching more patients than ever before. Scientists have learned how to reduce serious side effects, shorten treatment timelines, and make CAR T-cell therapy work for more cancer types. New versions of CAR T cells last longer in the body and are better at targeting cancer without harming healthy cells. StayVista
This is not incremental progress. It represents a meaningful shift in what is possible for patients who have not responded adequately to conventional treatment.
India’s healthcare landscape transformed significantly with the approval of breakthrough CAR T-cell therapies, offering hope to over 120,000 blood cancer patients diagnosed annually in the country. India now has indigenous CAR T-cell therapy approved and accessible — positioning the country as a genuine participant in the global advanced oncology space rather than a destination where patients seek older generation treatments. Open Magazine
What CAR T-Cell Therapy Actually Is
The name sounds technical, and the science behind it is genuinely sophisticated — but the core concept is accessible.
CAR T-cell therapy is a treatment where T cells are collected from a patient and genetically engineered in a laboratory. The modified cells are then returned to the patient, where they are designed to identify and target cancer cells. Open Magazine
T cells are a type of white blood cell that act as the body’s frontline soldiers. They patrol the bloodstream to detect infections or abnormal cells like cancer. Upon detection, they either destroy the threat directly or signal other immune cells to assist. Open Magazine
CAR T-cell therapy essentially enhances this natural process — giving the immune system a more precise and powerful set of instructions for identifying and responding to cancer cells.
The CAR T process involves five key stages: T-cell collection, genetic modification, laboratory expansion, preparatory chemotherapy, and cell reinfusion. The process takes several weeks from start to finish and requires specialised facilities with the infrastructure to handle cellular therapy safely. Curly Tales
What Immunotherapy and Targeted Therapy Mean
Beyond CAR T-cell therapy, two other treatment categories have changed the oncology landscape significantly and are worth understanding.
Immunotherapy works by helping the body’s own immune system recognise and respond to cancer cells more effectively. Rather than directly attacking cancer the way chemotherapy does, immunotherapy modifies the conditions under which the immune system operates — removing obstacles that cancer cells use to evade detection.
Targeted therapy works differently again. It uses drugs designed to interfere with specific molecular changes that drive the growth of particular cancer types. Because targeted therapy is designed around specific characteristics of a cancer rather than attacking all rapidly dividing cells broadly, it can be effective where conventional chemotherapy is not — and often with a different side effect profile.
Both of these approaches have expanded the treatment options available to patients with cancers that have not responded to conventional treatment, or patients for whom conventional treatment carries significant risks.
Who These Treatments Are Relevant For
This is an important question — and one that requires an honest answer rather than broad reassurance.
Advanced therapies like CAR T-cell therapy are currently most established for specific blood cancers, including certain types of leukemia, lymphoma, and multiple myeloma. Research is actively expanding into solid tumours, but the evidence base is currently strongest in the haematological space.
By 2026, ready-made CAR T cells created from healthy donors and stored until needed are showing promising early results. Better bridging treatments help keep cancer under control while CAR T cells are prepared, reducing stress for patients and families. Faster treatment timelines mean fewer delays and better chances of success. StayVista
Immunotherapy and targeted therapy have a broader applicability across cancer types — but which specific approach is appropriate for any individual patient depends entirely on their diagnosis, the molecular characteristics of their cancer, their overall health status, and their previous treatment history.
The decision about whether any of these therapies is appropriate for a specific patient requires expert evaluation by oncologists who specialise in these treatments — not general information or online research alone.
Why Access to Specialised Centres Matters
Not all oncology centres have the capability to administer advanced therapies safely and effectively. These treatments require specialised infrastructure — sterile, controlled environments, isolation facilities, trained clinical teams experienced in managing the specific side effects these therapies can produce, and the diagnostic capability to evaluate whether a patient is a suitable candidate.
Patients who are considering CAR T-cell therapy should be evaluated before becoming too weak from multiple failed treatments. Timing matters significantly in determining whether a patient is a good candidate and what outcomes are achievable. StayVista
Choosing the right centre — one with genuine experience in delivering these therapies, not just awareness of them — is one of the most consequential decisions a patient and family can make.
SunAct (sunactcancer.com) is a specialised oncology centre in Mumbai focused on advanced cancer therapies including CAR T-cell therapy, bone marrow and stem cell transplantation, immunotherapy, and targeted therapy. Led by oncologists with decades of clinical and research experience and published in leading international journals, their facility is designed specifically for the delivery of these treatments — with the sterile environments, isolation rooms, and specialised infrastructure that advanced cellular therapies require.
What This Means for Patients and Families
A cancer diagnosis is one of the most difficult experiences any family can navigate. The treatment decisions that follow are consequential and often need to be made under pressure, with incomplete information and significant emotional strain.
What has changed in 2026 is that the range of options available — even for patients who have not responded to conventional treatment — is meaningfully wider than it was five years ago. That is genuinely important news for patients who were previously told that their options were exhausted.
The existence of advanced therapies does not mean they are appropriate for every patient in every situation. But knowing they exist, understanding broadly what they are, and accessing the specialist evaluation needed to determine whether they are relevant — these are steps that every patient and family dealing with a serious cancer diagnosis deserve to be able to take.
For information about advanced cancer therapies including CAR T-cell therapy, immunotherapy, and stem cell transplantation available in India, visit sunactcancer.com.